A major clinical trial presented at the ESC Congress 2026 has introduced a compelling new dimension to the long-standing debate over how clinicians identify patients who require statin therapy to prevent heart attacks and strokes. The CorCal Outcomes trial, which evaluated the efficacy of coronary artery calcium (CAC) scanning against traditional risk assessment algorithms, found that utilizing heart scans led to significantly fewer recommendations for statin initiation. Despite this reduction in prescribing, the observed rate of major cardiovascular events remained identical between the two study groups.

The findings, shared during a high-profile "Hot Line" session at the conference, also highlighted a striking, secondary outcome: patients who were advised to begin statin therapy based on the visual evidence of calcium buildup in their arteries were substantially more likely to adhere to their medication regimens than those whose treatment decisions were based on standard risk calculators. While the study results suggest that heart scans could allow for more targeted and personalized treatment decisions, the researchers cautioned that the trial did not definitively establish that the scan-based approach is as effective as conventional risk assessment. They emphasized that further research is required to determine whether this diagnostic strategy offers a superior or safer pathway for the prevention of cardiovascular disease.

Why Predicting Heart Disease Risk Remains a Challenge

Cardiovascular disease continues to hold its position as the world’s leading cause of morbidity and mortality. A significant portion of this global health burden is attributed to atherosclerotic cardiovascular disease (ASCVD). This condition develops insidiously as fatty deposits—known as plaque—gradually accumulate within the walls of the arteries. Over time, these deposits can restrict blood flow, significantly increasing the risk of life-threatening events such as myocardial infarction (heart attack) and ischemic stroke.

In clinical practice, physicians rely on a variety of well-established risk factors to estimate a patient’s susceptibility to ASCVD. These include smoking status, the presence of diabetes, elevated blood pressure, and high levels of cholesterol. By inputting these metrics into standardized calculators, doctors determine whether a patient is a candidate for preventive interventions. Statins, which function by lowering levels of low-density lipoprotein (LDL) cholesterol—often colloquially referred to as "bad" cholesterol—are the cornerstone of this preventative approach. By reducing circulating cholesterol, these medications lower the risk of serious cardiovascular complications.

However, the clinical challenge lies in the precision of these assessments. Many individuals who eventually suffer a major cardiovascular event do not appear to be at high risk when evaluated through conventional screening methods.

"For far too many patients, the first symptom of ASCVD is a heart attack," explained Dr. Joseph B. Muhlestein of the Intermountain Medical Center in the United States, who served as the Principal Investigator of the CorCal Outcomes trial. "Statins have been shown to be highly effective in the prevention of ASCVD; however, there is a major gap in risk assessment, statin initiation, and statin persistence."

Dr. Muhlestein noted that many individuals, particularly younger adults who go on to suffer an initial heart attack, would not have been classified as "high risk" under traditional models. This persistent limitation has led the medical community to investigate whether directly visualizing the arteries—rather than merely calculating risk based on clinical markers—might yield more actionable data.

Can Heart Calcium Scans Improve Statin Decisions?

The CorCal Outcomes trial was designed to compare two distinct philosophies of preventative care. The first approach utilized the "pooled cohort equations" (PCE), the current standard in many clinical settings. This tool estimates an individual’s 10-year risk of developing cardiovascular disease by integrating variables such as age, total cholesterol, HDL cholesterol, blood pressure, and smoking status.

The second approach relied on the measurement of coronary artery calcium (CAC). Using a non-invasive computed tomography (CT) scan, clinicians can detect the presence of calcium deposits in the coronary arteries. Because calcium often accumulates within atherosclerotic plaque, its presence serves as a highly specific marker for underlying coronary artery disease, often appearing in patients who remain entirely asymptomatic. While traditional risk calculators provide a statistical estimate of future risk, CAC scans provide a tangible snapshot of the disease already present in the patient’s vascular system.

Nearly 5,800 Patients Put Both Methods to the Test

To evaluate these methods, the trial enrolled 5,772 patients from the Canyons and Desert regions of Intermountain Health Care. The study population was strictly defined: participants had no known history of ASCVD or diabetes and had not previously been prescribed statin therapy. The cohort was demographically balanced, with a mean age of 64 years and a participant pool that was 51% female.

Participants were randomized in a 1:1 ratio into two study arms. The first group received treatment recommendations based on the traditional PCE risk scores, while the second group received guidance derived from their CAC scan results. Both the patients and their primary care physicians were made aware of the recommendations generated by the study protocol, though the final decision regarding the initiation of statin therapy remained a collaborative choice between the patient and their doctor.

The primary endpoint of the study was a composite of major adverse cardiovascular events (MACE), defined as all-cause mortality, myocardial infarction, stroke, and arterial revascularization. Researchers tracked these outcomes over an average follow-up period of 4.2 years.

Heart Scans Led to Far Fewer Statin Recommendations

The results of the trial provided a surprising look at clinical practice patterns. After the follow-up period, researchers found that the rate of major cardiovascular events was identical in both groups, occurring in 2.7% of all patients. The estimated relative risk was effectively the same, with a hazard ratio of 0.99 and a 95% confidence interval of 0.71 to 1.38.

While the outcomes were consistent, the study failed to meet its pre-specified statistical requirement to prove that the CAC-based strategy was non-inferior to the conventional approach. However, the most significant divergence between the two groups was the volume of prescriptions generated. Participants assessed through traditional risk scores were recommended for statin therapy more than three times as often as those whose treatment plans were guided by their calcium scan results. Despite this dramatic difference in how many patients were placed on medication, the protective outcomes remained on par between the two groups.

A Surprising Difference in Statin Adherence

Beyond the clinical event rates, the trial uncovered a compelling psychological or behavioral finding: adherence to treatment. Among the patients who were advised to start statins, those who had received the recommendation based on their CAC score were significantly more likely to continue taking their medication compared to those assessed via traditional risk factors.

The adherence rates were stark, with 62% of the CAC-guided group maintaining their regimen compared to only 23% in the traditional assessment group. Patients guided by the results of their heart scans were approximately 2.7 times more likely to follow their prescribed treatment. While the trial did not specifically investigate the psychological mechanisms behind this, researchers hypothesize that seeing tangible evidence of disease within their own arteries may provide patients with a greater sense of urgency and motivation regarding their cardiovascular health.

What the Findings Mean for Heart Disease Prevention

Despite these insights, the researchers cautioned that the lower-than-anticipated rate of cardiovascular events across the entire study population limited the trial’s statistical power. "The power of the study to detect a difference was reduced by the lower-than-expected event rates, and we did not demonstrate non-inferiority between the groups," Dr. Muhlestein remarked. He emphasized that the findings should be viewed as hypothesis-generating, providing a roadmap for future, larger-scale trials.

The data generated by the CorCal Outcomes trial are timely, as medical organizations continue to refine their approach to preventative cardiology. The 2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidemias already suggests that clinicians consider using CAC scores as an additional tool in risk assessment, particularly for patients whose risk profile sits at a borderline or moderate level.

As the medical community moves toward more personalized medicine, the question remains whether the use of imaging technologies like coronary calcium scans can optimize the efficiency of preventative prescribing without compromising patient safety. By potentially improving both the precision of who is treated and the likelihood that those patients will actually adhere to their life-saving medication, the CorCal Outcomes trial provides a foundation for the next generation of cardiovascular prevention strategies. Whether this shift will lead to better long-term outcomes remains a focal point for future investigation.